Mel-Mont Medical Secures $6.9M

Mel-Mont Medical has secured $6.9 million in funding from investors.

Founded in 2014, the company is dedicated to developing user-friendly self-sampling devices for comprehensive HPV-related cancer testing.

This approach aims to revolutionize patients’ ability to detect disease early, when treatment can be most effective, thereby increasing survival rates.

By offering convenient and comfortable self-collection coupled with advanced molecular tests, Mel-Mont Medical seeks to empower individuals to take control of their health, particularly those who may face geographic or financial barriers to preventative healthcare.

The company's first product, the Mia Comprehensive Cervical Cancer Test, provides a comfortable alternative to a standard Pap smear.

It tests for high-risk HPV strains and oncogenic activity that may lead to cervical cancer.

The Mia HPV E6/E7 mRNA test has undergone rigorous validation in global clinical trials involving over 127,000 women, with scientific evidence highlighted in 27 peer-reviewed publications.

In 2024, the American Medical Association granted the Mia Test its own PLA code, 0463U, a step designed to streamline reimbursement and enhance accessibility for women.

This newly secured capital of $6.9 million will significantly bolster Mel-Mont Medical's ongoing growth initiatives.

The funds are expected to advance the development and commercialization of its novel technologies and medical services, particularly as it seeks to expand the availability of its self-sampling solutions.

This investment underscores the potential impact of accessible early detection methods in improving public health outcomes.

Mel-Mont Medical remains committed to its mission of preserving life through the prevention and early diagnosis of health conditions related to RNA viruses.

The company plans to continue relying on qualified and humanized personnel and high-quality equipment to provide security and confidence to its patients.

With this funding, Mel-Mont Medical looks forward to expanding its reach and impact in preventative healthcare, empowering more individuals globally.